Summer School on Cardiovascular Prevention
Expand your knowledge on cardiovascular prevention!← Back to courses
- CIVIS focus area
- Open to
- Field of studies
- Medicine and Health
- Course dates
- 25-27 May & 23 June 2022
A group of renowned specialists have developed an ambitious program starting on the pathogenesis of atherothrombosis, CV risk evaluation, including scores, biomarkers, imaging and genetics. Then, the focus will be on the different CV risk factors and their treatment, including pipeline therapies. Finally, the role of anti-inflammatory drugs and cardiac rehabilitation will be discussed.
Main topics addressed
- Pathogenesis of atherothrombosis
- Stratification of cardiovascular risk: risk scores
- Role of non-invasive imaging techniques in cardiovascular prevention
- Role of invasive imaging techniques in cardiovascular prevention
- Biomarkers: really useful in our daily practice?
- Hemostasis biomarkers
- The role of genetics in CV prevention
- The role of dyslipidemias in cardiovascular disease
- Nutrition for cardiovascular prevention, lipoproteins and CV risk
- Present therapies for dyslipidemia. Mechanisms of action and evidence supporting their use
- The pipeline of therapies for dyslipidemia
- Antidiabetic therapy and cardiovascular risk reduction
- Management of smoking
- Treating hypertension in 2022
- Antithrombotic therapy in cardiovascular prevention
- The role of cardiac rehabilitation
- Anti-inflammatory drugs: a new player in the field of CV prevention
- Extensive knowledge on CV risk evaluation: scores, imaging, genetics, and biomarkers
- Current state-of-the-art on cardiovascular risk factors and their treatment, including pipeline therapies and the role of anti-inflammatory drugs
- The value of cardiac rehabilitation on cardiovascular prevention
- Gaps in evidence, in order to provide the students with a basis to initiate a research career
|Dates: 25-27 May & 23 June 2022||Language: English (B2)|
|Format: Blended||Places for CIVIS students: 30-60|
|Location: Madrid, Spain||Contact hours: 25|
|ECTS: 3*||Individual workload: 50|
* The recognition of ECTS depends on your home university.
The course is organised into 19 lessons:
- 7 lessons on 25 May 2022
- 6 lessons on 26 May 2022
- 6 lessons on 27 May 2022
The presentation of the research project will take place on 23 June 2022.
This CIVIS course is open to Master and PhD students enrolled in medicine, pharmacology, chemistry or biology at one of CIVIS member universities.
A B2 level of English is recommended.
To register, click here and fill in the online registration form.
Selected students will be notified on 4 May 2022.
Should you have any questions about the application process or about the course, please contact the organiser of the course:
The students will be divided into groups of 5 students maximum and each one will present a research project on cardiovascular prevention.
General Eligibility Criteria for CIVIS Courses
Applicants need to be enrolled at their home university in order to be eligible for selection and participation. If uncertain about your status at your home university (part-time or exchange students etc) please check with your home university’s website or International Office.
Applicants who will be receiving other Erasmus funds for the duration of the course are not entitled to funding. Participation in the course may still be possible under “zero-grant” status, but applicants should contact their home university in order to confirm this.
A list of links and contacts for each university can be found in this Q&A.
- José Tuñón Head, Department of Cardiology, Fundación Jiménez Díaz. Professor and Chairman of the Department of Medicine, Universidad Autónoma de Madrid. H índex 45.
- Massimo Volpe, Chair of Cardiology, Director of the Specialty School in Cardiovascular Disease, Department of Clinical and Molecular Medicine. Faculty of Medicine and Psychology, Sapienza Università di Roma. Pro-Rector Research Planning, Sapienza Università di Roma.
- G Tocci Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza Università di Roma.
- B Musumeci. Cardiology Division, Clinical and Molecular Medicine Department, Sapienza Università di Roma.
- Elvin Khedi, Director Innovation Clinic Hospital Erasme ULB Brussels Belgium.
- Philippe Van de Borne, Department of Cardiology, Erasme Hospital. Université libre de Bruxelles, Brussels, Belgium.
- Iordanis Mourouzis, Associate Professor Department of Pharmacology, School of Medicine, National and Kapodistrian University of Athens.
- Nikolaos Tentolouris, Professor 1st Department of Propaedeutic and Internal Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens.
- Françoise Dignat-George, Dean of the Faculty of Pharmacy Professor of Hematology and Immunology - Aix-Marseille Université. Vice President of Technology Transfer and Innovation - Aix-Marseille Université Deputy Director of the Center for CardioVascular and Nutrition research - C2VN. Director of Department of Hematology et Immunology – AP-HM.
- Sophie Beliard, Aix Marseille Université, APHM, INSERM, INRAE, C2VN, Marseille, APHM, Department of Nutrition, Metabolic Diseases, Endocrinology, University Hospital La Conception, Marseille.
- Carmen Ayuso, Head, Department of Genetics, Fundación Jiménez Díaz, Madrid, Associate Professor of Genetics, Universidad Autónoma de Madrid. Field: Genetics, H index: 59.
- Germán Peces-Barba, Associate Chief, Department of Neumology, Fundación Jiménez Díaz, Associate Professor, Universidad Autónoma de Madrid.
- Mónica Recio, Staff, Department of Cardiology, Fundación Jiménez Díaz.
- Andrea Kallmeyer, Staff, Coronary Unit, Department of Cardiology, Fundación Jiménez Díaz.
- Fernando Civeira, Professor of Medicine, Specialist in lipids. H index: 41, Zaragoza University.